Hello fellow traders, I hope you are all doing well.
Key Observations:
1. Strong Support Zone: JUBLPHARMA has reached a strong zone that previously acted as resistance and could now turn into support.
2. Chart Pattern: A falling wedge pattern is visible, which is typically a bullish reversal signal. We can also see that the breakout has already happened and now the price has come to retest.
3. Bullish Engulfing Candle: On the weekly time frame, we see buying pressure emerging, confirmed by a Bullish Engulfing candle.
4. Entry Point: A good entry could be above ₹1010 for better confirmation of the uptrend.
5. Targets: The potential targets are already marked on the chart as T1, T2, and T3.
As this is my first published idea, I kindly ask you to ignore any mistakes, and I will strive to improve in the future.
Disclaimer:
This is purely an analysis and not investment advice. Please trade with due diligence and manage your risks carefully.
I hope you like my work, Thanks in advance.
Best regards - Anantesh
Key Observations:
1. Strong Support Zone: JUBLPHARMA has reached a strong zone that previously acted as resistance and could now turn into support.
2. Chart Pattern: A falling wedge pattern is visible, which is typically a bullish reversal signal. We can also see that the breakout has already happened and now the price has come to retest.
3. Bullish Engulfing Candle: On the weekly time frame, we see buying pressure emerging, confirmed by a Bullish Engulfing candle.
4. Entry Point: A good entry could be above ₹1010 for better confirmation of the uptrend.
5. Targets: The potential targets are already marked on the chart as T1, T2, and T3.
As this is my first published idea, I kindly ask you to ignore any mistakes, and I will strive to improve in the future.
Disclaimer:
This is purely an analysis and not investment advice. Please trade with due diligence and manage your risks carefully.
I hope you like my work, Thanks in advance.
Best regards - Anantesh
交易开始
Trade is now active and it has reached T1.交易结束：到达止损
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。